glp 1 news today GLP-1 receptor agonists show promise in treating substance use disorders As interest in GLP-1 medication

10.1016/j.cardfail.2006.08.211

Part 2: management

Furthermore, in the EMPA-REG OUTCOME trial, empagliflozin reduced the risk of both pump failure and sudden deaths (46)

Fracture Risk Data from GLP1 Trials Several cardiovascular outcomes trials (CVOTs) have collected fracture data as secondary outcomes: Trials involving semaglutide and dulaglutide generally report fracture rates similar to placebo A few studies suggest a potential increase in non-vertebral fractures, though findings are inconsistent and often not statistically significant One important confounder is weight loss, which itself can lead to bone loss

Apart from these cardiovascular mechanisms, increased BMI independently correlates with mortality risk